Pay in 4 interest-free payments of $7.11 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
therefore, longer half-life synthetic analogs have been developed for clinical use, as a new class of antidiabetic agents ( The anti-inflammatory potential of GLP1-RAs (Glucagon-like peptide-1 receptor agonists) could depend on their direct effect on immune cells, an indirect effect caused by weight loss, or a combination of the two
Follow-up ranged from 12 months to 9 years
These 3.8 million Part D enrollees met the clinical criteria, did not have a diagnosis of type 2 diabetes, OSA, or MASH, or a GLP-1 Part D-covered prescription in 2023, and could be eligible for the Medicare GLP-1 Bridge, assuming no changes in diagnosis or GLP-1 use in Part D in 2026
About the speakers: Patricia Davidson DCN, RDN, LDN, CDCES, FAND, CHSE, FADCES is a Professor of Nutrition at West Chester University-PA
& Devaraj, N
